文献速递甲状腺与浅表头颈US

单次高强度聚焦超声治疗持续性或复发性Graves病:前瞻性研究的初步经验

Single-Session High-Intensity Focused Ultrasound Treatment for Persistent or Relapsed Graves Disease: Preliminary Experience in a Prospective Study.
PubMed 文献 · Radiology · 2017-07-20

这项前瞻性试验于2015年11月至2016年2月纳入30例持续性或复发性Graves病患者,行超声引导下高强度聚焦超声消融,技术成功率96.7%,12个月复发率26.7%(95%CI 14.19%, 44.95%),TSHR抗体与腺体体积与复发相关,作者认为该治疗可能安全有效但需进一步研究。

要点

  • 超声引导高强度聚焦超声消融甲状腺的技术成功率为96.7%。
  • 12个月复发率为26.7%(95%CI 14.19%, 44.95%),复发指FT4>23 pmol/L。
  • TSHR抗体(OR=1.414)与腺体体积(OR=0.557)与12个月复发相关。

核心结论

  • 超声引导下甲状腺高强度聚焦超声消融对持续性或复发性Graves病可能安全有效,但作者认为在其成为该适应证的主流治疗前仍需进一步研究。

研究设计与样本

  • 前瞻性试验(NCT02685514),2015年11月至2016年2月纳入30例,对双侧甲状腺叶行超声引导高强度聚焦超声消融,气管食管沟及颈总动脉邻近区域不予消融。

诊断标准与关键数值

  • 复发定义为治疗后甲状腺功能亢进(FT4>23 pmol/L),12个月复发率26.7%(95%CI 14.19%, 44.95%)。

临床应用与阅片要点

  • 作者认为超声引导甲状腺高强度聚焦超声消融对持续性或复发性Graves病可能安全有效,但在成为该适应证主流治疗前仍需进一步研究。

局限性

  • 作者指出在其成为该适应证主流治疗前仍需进一步研究。
  • 原文报告1例(3.3%;95%CI 0.59%, 16.67%)声带麻痹、2例(6.7%;95%CI 1.85%, 21.33%)Horner综合征,均非永久性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To evaluate the safety and efficacy of ultrasonography (US)-guided high-intensity focused ultrasound (HIFU) ablation as a treatment for medically refractory Graves disease (GD). Materials and Methods After ethics approval, a prospective trial (NCT02685514) was performed from November 2015 to February 2016. Thirty patients underwent ablation of the entire right and left thyroid lobes, with areas near the tracheal-esophageal groove and common carotid artery left unablated. Serum thyroid-stimulating hormone (TSH), free T4 (FT4), antithyroid autoantibodies, and TSH receptor (TSHR) antibody levels were evaluated afterward, and US color Doppler, US volumetry, and eye assessment were performed. The primary outcome was the 12-month relapse rate. Relapse referred to hyperthyroidism (FT4 > 23 pmol/L) afterward. Variables associated with relapse were analyzed by using binary logistic regression. Results The technical success rate was 96.7%. The cohort comprised entirely women, with a median age of 38.2 years (interquartile range, 29.5-49.0 years). After 12 months, eight patients (26.7%; 95% confidence interval [CI]: 14.19%, 44.95%) experienced relapse. One patient (3.3%; 95% CI: 0.59%, 16.67%) experienced vocal cord palsy, while two patients (6.7%; 95% CI: 1.85%, 21.33%) experienced Horner syndrome, but none of these conditions were permanent. No changes in gland volume, antithyroid autoantibody levels, and ophthalmic parameters were found at 12-month follow-up. Baseline TSHR was found to have decreased significantly at 6- and 12-month follow-up (P < .001 for both). TSHR antibody (odds ratio [OR] = 1.414; 95% CI: 1.018, 1.965; P = .039) and gland volume (OR = 0.557; 95% CI: 0.353, 0.880; P = .012) were associated with 12-month relapse, with higher antibody levels conferring a higher likelihood and smaller gland volumes conferring a lower likelihood. Conclusion US-guided HIFU of the thyroid may be a safe and efficacious treatment in patients with persistent or relapsed GD. However, further study is warranted before it can become mainstream for this indication. © RSNA, 2017 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Lang BH, Woo YC, Wong IY, et al. Single-Session High-Intensity Focused Ultrasound Treatment for Persistent or Relapsed Graves Disease: Preliminary Experience in a Prospective Study. Radiology. 2017. PMID: 28727542. doi:10.1148/radiol.2017162776

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。